SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETRs rally and announced share-repurchase program have fueled intense speculation about a short squeeze, with traders pointing to the small float, elevated short interest and tight share availability. Many are bullish on the setup, while others say a squeeze is unconfirmed and needs sustained buying volume; the companys turnaround updates are also in focus.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGR is drawing attention amid a sharp, sustained selloff, with bearish traders pointing to insider and investor share overhang, stock-based compensation, and doubts about management. Bulls counter that loan-marketplace growth, profitability, and the companys tokenization opportunity remain intact, making the debate center on whether the decline reflects fundamental concerns or selling pressure.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

A strong tech-led Nasdaq rally has pressured SQQQ, while traders debate whether concerns about AI spending and stretched tech valuations could spur a pullback and lift the inverse fund. Some are adding SQQQ as a hedge or bearish trade, while others warn that continued tech strength and the ETFs daily-reset decay can erode returns.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp, sustained selloff in silver and SLV, including a break below a key psychological support level, dominates the discussion. Many traders expect further losses or favor shorting, while others see the decline as oversold and a chance to accumulate; claims of market manipulation remain speculation.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention over a technology-sector pullback tied to AI and semiconductor weakness, with traders citing poor breadth, technical deterioration and rotation toward defensive sectors. Views are split between seeing a potential bottom or healthy consolidation and warning that the rebound is weak and losses could deepen.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention as biotech attempts a modest rebound after broad sector selling, while traders watch whether the recovery can hold despite the ETF remaining below its 50-day average. Some see washed-out valuations, upcoming catalysts and M&A activity as supportive; others point to rate sensitivity and macro uncertainty as reasons for continued choppiness.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational adjunctive treatment for major depressive disorder. Many traders are optimistic about the readout and point to insider buying, while others emphasize the binary trial risk, uncertainty that earlier results will hold up, and potential dilution.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Reports of cracked inner screens on Apples new foldable iPhone Duo are driving concern about product quality and possible damage to the launch, though traders disagree over whether the failures are widespread or isolated and point to strong demand. Apple has acknowledged an issue affecting a small number of devices and is offering replacements.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas large share offering and planned future share-sale program to fund its AI infrastructure buildout are driving discussion, alongside concerns about rising capital spending and negative free cash flow. Traders are split between viewing the financing as dilutive and a sign of mounting costs, or as a way to secure funding for AI investment; the stocks sharp swings have fueled both bearish calls and dip-buying.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas stronger-than-expected third-quarter results and raised outlook, including a robust forecast for 2027, drove attention as investors weighed demand for AI data-center infrastructure. Bulls see the results as confirmation of sustained growth, while skeptics point to volatile trading, margin and cash-flow concerns, and the risk that AI spending expectations may prove too high.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DFTX Q2 &#39;26 Earnings Results &amp; Recap

Definium Therapeutics reported a net loss of $158.986 million for the three months ended June 30, 2026, with cash, cash equivalents and investments totaling approximately $1.1 billion at period end.

Brock Lohnes

Bob Reams

Stocktwits

Definium Therapeutics Inc.

 Q2 '26 Earnings Results & Recap

Definium Therapeutics reported a net loss of $158.986 million for the three months ended June 30, 2026, with cash, cash equivalents and investments totaling approximately $1.1 billion at period end.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

StockTwits for iOS

San Juan

@StocktwitsEarnings This is a decent high-level summary, but I’d put the items into perspective.

Bullish

* Phase 3 efficacy was positive. This is the biggest item by far. For a clinical-stage biotech, successful Phase 3 data is often far more important than quarterly earnings.
* $1.1 billion in cash is a major strength. It gives the company years of runway to pursue FDA approval and commercialization without immediate financing concerns.

Bearish

The “bearish takeaway” is somewhat overstated.

* Large net loss: Expected. Clinical-stage biotech companies almost always lose money because they’re spending heavily on trials rather than selling products.
* No revenue: Also expected. Until a drug is approved, there usually isn’t meaningful product revenue.
* Warrant liabilities: These are largely non-cash accounting adjustments. They can make reported earnings look much worse without affecting the company’s day-to-day cash position.
* “Necessitating ongoing capital raises”? QUESTIONABLE!!

 This is a decent high-level summary, but I’d put the items into perspective.

Bullish

* Phase 3 efficacy was positive. This is the biggest item by far. For a clinical-stage biotech, successful Phase 3 data is often far more important than quarterly earnings.
* $1.1 billion in cash is a major strength. It gives the company years of runway to pursue FDA approval and commercialization without immediate financing concerns.

Bearish

The “bearish takeaway” is somewhat overstated.

* Large net loss: Expected. Clinical-stage biotech companies almost always lose money because they’re spending heavily on trials rather than selling products.
* No revenue: Also expected. Until a drug is approved, there usually isn’t meaningful product revenue.
* Warrant liabilities: These are largely non-cash accounting adjustments. They can make reported earnings look much worse without affecting the company’s day-to-day cash position.
* “Necessitating ongoing capital raises”? QUESTIONABLE!!